XML 89 R78.htm IDEA: XBRL DOCUMENT v3.25.3
Segment Reporting - Schedule of Reconciliation of Segment Profits to Income before Taxes (Details) - USD ($)
$ in Millions
 3 Months Ended 9 Months Ended
Sep. 30, 2025
Sep. 30, 2024
Sep. 30, 2025
Sep. 30, 2024
Segment Reporting Information [Line Items]        
Sales $ 17,276 $ 16,657 $ 48,611 $ 48,544
Less segment costs:        
Cost of sales 3,855 4,080 10,831 11,365
Selling, general and administrative 2,633 2,731 7,835 7,952
Research and development (4,234) (5,862) (11,903) (13,354)
Other segment items 238 162 281 151
Total segment profits 6,745 4,090 17,647 15,766
Other profits 6,745 4,090 17,647 15,766
Unallocated:        
Interest income 96 127 274 269
Interest expense (327) (330) (946) (943)
Amortization     (1,820) (1,720)
Depreciation     (1,552) (1,582)
Research and development (4,234) (5,862) (11,903) (13,354)
Restructuring costs (47) (56) (676) (258)
Total segment profits        
Segment Reporting Information [Line Items]        
Sales 17,226 16,430 48,148 47,838
Less segment costs:        
Total segment profits 13,049 12,057 36,001 35,225
Other profits 13,049 12,057 36,001 35,225
Unallocated:        
Depreciation (83) (86) (207) (214)
Total segment profits | Pharma- ceutical        
Segment Reporting Information [Line Items]        
Sales 15,611 14,943 43,299 43,358
Less segment costs:        
Cost of sales 1,664 1,904 4,838 5,319
Selling, general and administrative 1,469 1,519 4,327 4,462
Research and development 0 0 0 0
Other segment items (60) (27) (130) (74)
Total segment profits 12,538 11,547 34,264 33,651
Other profits 12,538 11,547 34,264 33,651
Unallocated:        
Depreciation (1) (1) (4) (3)
Research and development 0 0 0 0
Total segment profits | Animal Health        
Segment Reporting Information [Line Items]        
Sales 1,615 1,487 4,849 4,480
Less segment costs:        
Cost of sales 710 613 1,968 1,838
Selling, general and administrative 277 268 822 791
Research and development (118) (95) (323) (276)
Other segment items (1) 1 (1) 1
Total segment profits 511 510 1,737 1,574
Other profits 511 510 1,737 1,574
Unallocated:        
Depreciation (82) (85) (203) (211)
Research and development (118) (95) (323) (276)
Other profits        
Segment Reporting Information [Line Items]        
Sales 50 227 463 706
Less segment costs:        
Research and development (3,839) (5,716) (11,159) (12,926)
Total segment profits 4 117 235 391
Other profits 4 117 235 391
Unallocated:        
Interest income 96 127 274 269
Interest expense (327) (330) (946) (943)
Amortization (623) (633) (1,820) (1,720)
Depreciation (449) (467) (1,345) (1,368)
Research and development (3,839) (5,716) (11,159) (12,926)
Restructuring costs (47) (56) (676) (258)
Other unallocated, net $ (1,119) $ (1,009) $ (2,917) $ (2,904)